CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers

1. Tang, D. et al. Identification of key pathways and genes changes in pancreatic cancer cells (BXPC-3) after cross-talk with primary pancreatic stellate cells using bioinformatics analysis. Neoplasma 66(5), 681–693 (2019).

   Google Scholar 

2. Gyoten, M. et al. Lovastatin treatment inducing apoptosis in human pancreatic cancer cells by inhibiting cholesterol rafts in plasma membrane and mitochondria. Int J Mol Sci. 24(23), 16814 (2023).

   Google Scholar 

3. Nerwal, A. et al. Neoadjuvant chemotherapy with chemoradiotherapy for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma-retrospective review from a tertiary care hospital. Asia Pac. J. Clin. Oncol. 21(4), 392–398 (2025).

   Google Scholar 

4. Yang, L. et al. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal. Transduct Target Ther. 8(1), 35 (2023).

   Google Scholar 

5. Drizyte-Miller, K. et al. KRAS: the Achilles’ heel of pancreas cancer biology. J. Clin. Invest. 135(16), e191939 (2025).

   Google Scholar 

6. Satoi, S. et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepatobiliary Pancreat Sci. 20(6), 590–600 (2013).

   Google Scholar 

7. Jameson, G. S. et al. Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b/2 pilot clinical trial. JAMA Oncol. 6(1), 125–132 (2020).

   Google Scholar 

8. Calabretta, S. et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35(16), 2031–2039 (2016).

   Google Scholar 

9. Browning, R. J. et al. Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. J. Control Release. 337, 371–377 (2021).

   Google Scholar 

10. Zhou, G. et al. A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy. J. Mater. Chem. B. 13(11), 3716–3729 (2025).

    Google Scholar 

11. Li, X. et al. Oridonin: a review of its pharmacology. Pharmacokinetics and Toxicity. Front Pharmacol. 12, 645824 (2021).

    Google Scholar 

12. Liu, R. et al. Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. Cancer Cell Int. 24(1), 348 (2024).

    Google Scholar 

13. Shao, B. et al. Autophagy-dependent apoptosis induction by oridonin are mediated by ROS-dependent AMPK-mTOR-ULK1 pathway in colon cancer. Am. J. Cancer Res. 15(4), 1902–1918 (2025).

    Google Scholar 

14. Qi, X. et al. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int. J. Nanomedicine. 7, 1793–1804 (2012).

    Google Scholar 

15. Zhao, X. et al. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann. Trans. Med. 9(13), 1084 (2021).

    Google Scholar 

16. Li, P. et al. Hypoxia-responsive liposome enhances intracellular delivery of photosensitizer for effective photodynamic therapy. J. Control. Release. 377, 277–287 (2025).

    Google Scholar 

17. Sharma, G. et al. Revolutionizing Parkinson’s treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy. Drug. Deliv. Trans. Res. 15(8), 2589–2607 (2025).

    Google Scholar 

18. Lim, S. H. et al. Nanoparticle-based combinational strategies for overcoming the blood-brain barrier and blood-Tumor barrier. Int. J. Nanomedicine. 19, 2529–2552 (2024).

    Google Scholar 

19. Li, Y. et al. Nanomaterials based on hollow gold nanospheres for cancer therapy. Regen Biomater. 11, rbae126 (2024).

    Google Scholar 

20. Shah, T. et al. Computational design to experimental validation: molecular dynamics-assisted development of polycaprolactone micelles for drug delivery. J. Mater. Chem. B. 13(13), 4166–4178 (2025).

    Google Scholar 

21. El-Saadony, M. T. et al. Chitosan, derivatives, and its nanoparticles: Preparation, physicochemical properties, biological activities, and biomedical applications—a comprehensive review. Int. J. Biol. Macromol. 313, 142832 (2025).

    Google Scholar 

22. Pashkina, E. et al. Hyaluronic acid-based drug delivery systems for cancer therapy. Cells 14(2), 61 (2025).

    Google Scholar 

23. Liu, L. et al. Nanobody-based drug delivery systems for cancer therapy. J. Control. Release. 381, 113562 (2025).

    Google Scholar 

24. van der Koog, L. et al. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv. Healthc Mater. 11(5), e2100639 (2022).

    Google Scholar 

25. Odel, H. A. C. et al. Liposomes and niosomes: new trends and applications in the delivery of bioactive agents for cancer therapy. Int J Pharm. 668, 124994 (2025).

    Google Scholar 

26. Yu, B. et al. Empowering healthcare with phage display technology. ACS Biomater. Sci. Eng. 11(6), 3228–3248 (2025).

    Google Scholar 

27. Zhou, C. et al. Serine/threonine/tyrosine kinase 1 drives pancreatic carcinogenesis via GSK3β sequestration-mediated Wnt/β-catenin pathway hyperactivation. Signal Transduct Target Ther. 10(1), 205 (2025).

    Google Scholar 

28. Zhou, C. et al. B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. Signal Transduct Target Ther. 8(1), 66 (2023).

    Google Scholar 

29. Hu, C. M. et al. Innovative cyclic peptide disrupts IL-17RB-MLK4 interaction for targeted pancreatic cancer therapy. Biomed. Pharmacother. 184, 117892 (2025).

    Google Scholar 

30. Zhu, X. et al. Targeting pancreatic cancer cells with peptide-functionalized polymeric magnetic nanoparticles. Int. J. Mol. Sci. 20(12), 2988 (2019).

    Google Scholar 

31. Lu, L. et al. Preparation and characterization of PLGA-based magnetic polymer nanoparticles for targeting pancreatic adenocarcinoma. Curr. Pharm. Des. 29(9), 686–696 (2023).

    Google Scholar 

32. Valetti, S. et al. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J. Control. Release. 192, 29–39 (2014).

    Google Scholar 

33. Valetti, S. et al. Peptide conjugation: before or after nanoparticle formation?. Bioconjug Chem. 25(11), 1971–1983 (2014).

    Google Scholar 

34. Hou, L. et al. Effects of phytosterol butyrate ester on the characteristics of soybean phosphatidylcholine liposomes. J. Oleo Sci. 70(9), 1295–1306 (2021).

    Google Scholar 

35. Hong, C. et al. One stone four birds: a novel liposomal delivery system multi-functionalized with ginsenoside Rh2 for tumor targeting therapy. Nanomicro Lett. 12(1), 129 (2020).

    Google Scholar 

36. Sun, X. et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics. 7(2), 319–328 (2017).

    Google Scholar 

37. Papi, M. et al. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells. Nanoscale 9(29), 10327–10334 (2017).

    Google Scholar 

38. Bigdeli, A. et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10(3), 3723–3737 (2016).

    Google Scholar 

39. Corbo, C. et al. Effects of the protein corona on liposome-liposome and liposome-cell interactions. Int. J. Nanomedicine. 11, 3049–3063 (2016).

    Google Scholar 

40. Smith, C. et al. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J. Gastroenterol. 28(27), 3297–3313 (2022).

    Google Scholar 

41. Liu, Q. et al. Current research trends of nanomedicines. Acta Pharm. Sin B. 13(11), 4391–4416 (2023).

    Google Scholar 

42. Fang, J. et al. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug. Deliv Rev. 157, 142–160 (2020).

    Google Scholar 

43. Krishnan, N. et al. Cell membrane-coated nanoparticles for the treatment of cancer. Clin Transl. Med. 13(6), e1285 (2023).

    Google Scholar 

44. Jain, A. et al. Advances in tumor targeted liposomes. Curr. Mol. Med. 18(1), 44–57 (2018).

    Google Scholar 

45. Wang, S. et al. Liposomes for tumor targeted therapy: a review. Int. J. Mol. Sci. 24(3), 2643 (2023).

    Google Scholar 

46. Fathi, S. et al. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?. Future Med. Chem. 8(17), 2091–2112 (2016).

    Google Scholar 

47. Belfiore, L. et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. J. Control. Release. 277, 1–13 (2018).

    Google Scholar 

48. Deodhar, S. et al. Long circulating liposomes: challenges and opportunities. Ther. Deliv. 9(12), 857–872 (2018).

    Google Scholar 

49. Gao, C. et al. Preparation, characterization, and anti-colon cancer activity of oridonin-loaded long-circulating liposomes. Pharm. Dev. Technol. 26(10), 1073–1078 (2021).

    Google Scholar 

50. Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 15(7), 215–220 (1994).

    Google Scholar 

51. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772–781 (2013).

    Google Scholar 

52. Barrán-Berdón, A. L. et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29(21), 6485–6494 (2013).

    Google Scholar 

53. Mahmoudi, M. et al. Temperature: the “ignored” factor at the NanoBio interface. ACS Nano 7(8), 6555–6562 (2013).

    Google Scholar 

Download references

Author notes

1. Fangxia Zhang and Kunshun Luo have contributed equally to this work.

Authors and Affiliations

1. College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China

   Fangxia Zhang, Kunshun Luo, Teng Chen, Zhiyong Chen, Jing Yang, Ying Zhou, Tingting Feng, Yue Zhu & Zuhua Wang

2. Guizhou Key Laboratory of Modern Traditional Chinese Medicine Creation, Guiyang, China

   Fangxia Zhang, Kunshun Luo, Teng Chen, Zhiyong Chen, Jing Yang, Tingting Feng, Yue Zhu & Zuhua Wang

3. Department of Pharmacy, Shaoxing People’s Hospital, Zhongxing North Road 568, Shaoxing, 312000, China

   Shaoyan Xuan

Contributions

Kunshun Luo: Writing—original draft, Visualization, Conceptualization, Formal Analysis, Visualization, Review and Editing, Funding Acquisition; Fangxia Zhang: Writing-original draft, Visualization, Conceptualization, Formal Analysis, Visualization, Review and Editing; Teng Chen: Formal Analysis; Zhiyong Chen: Conceptualization, Formal Analysis; Jing Yang: Conceptualization; Ying Zhou: Funding Acquisition, Project Administration, Resources; Shaoyan Xuan: Funding Acquisition, Project Administration, Resources; Tingting Feng: Funding Acquisition, Project Administration, Resources; Yue Zhu: Conceptualization, project Administration, Resources, Formal Analysis; Zuhua Wang: Funding Acquisition, Project Administration, Resources, Conceptualization, Review and Editing.

Corresponding authors

Correspondence to Tingting Feng, Yue Zhu or Zuhua Wang.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Institutional review board statement

All experimental procedures presented in this manuscript were approved and carried out in accordance with the China Veterinary Animal Care Office Animal Experimental Ethics Committee of Guizhou University of Traditional Chinese Medicine (Grant No.20230022). This study was reported in accordance with ARRIVE guidelines.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions